Europe: More Direct-Acting Antivirals, More Controversy
The storms raging across Europe-and beyond-over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir).
The storms raging across Europe-and beyond-over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in combination for the treatment of chronic infection in adults.
The company will now start negotiations with each of the national pricing and reimbursement authorities in the EU countries where it wants to launch the product-and those negotiations will be conducted amid the turbulence created by arguments over the price for Gilead’s Sovaldi (sofosbuvir).
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
